CDK4 and lung adenocarcinoma: These results indicate that while concurrent combinations of a CDK4/6 inhibitor with etoposide and paclitaxel in GBM LN308 and lung adenocarcinoma A549 cell lines appeared to produce some additive cytotoxicity, similar to previously being reported [40], sequential schedules did not produce the same additivity.